New top UK research institute gets £3 million boost:
This article was originally published in Clinica
The University of Edinburgh has secured £38 million ($54 million) of the £50 million target funding for what promises to be a unique medical research institute, after the Wolfson Foundation last month pledged £4 million. The provisionally-named Research Institute for Medical Cell Biology, billed as the UK's first facility of its kind, will specialise in cardiovascular, reproductive and inflammatory diseases. Since securing half of the target funding by July 2001 (see Clinica No 965, p 8) it has also received £3 million from the Medical Research Council. It is due to open in 2004.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.